CellaVision AB : Year-end bulletin 2015

12.02.16 08:25
<strong>CELLAVISION AB</strong> : Year-end bulletin 2015

2015- A record year for CellaVision

October 1-December 31, 2015 

  • Net sales decreased by 15 % to SEK 61.6 million (72.5)
  • OpeRating profit was SEK 16.4 million (16.8).
  • The operating margin was 26.7 % (23.2).
  • Profit before tax was SEK 16.8 million (16.6).
  • Earnings per share were SEK 0.64 (0.49)

Significant events after the first quarter
  • Launch of the new CellaVision® CDMS 6.0 software and an update of CellaVision® Remote Review.
January 1-December 31, 2015 

· Net sales increased by 10 % to SEK 239.4 million (216.9).

· Operating profit increased to SEK 65.5 million (42.8).

· The operating margin increased to 27.3 % (19.7).

· Profit before tax increased to SEK 65.6 million (43.4).

· Earnings per share increased to SEK 2.22 (1.32).

· The Board of Directors proposes an increased dividend of SEK 1.50 per share for 2015 (1.00)

CEO's comments

2015 was a record year for CellaVision with a very strong increase in profitability and sound sales growth. The major follow-up order for the veterinary market contributed to a ten percent sales increase in 2015 to SEK 239.4 million (216.9). This, together with our indirect scalable business model, meant that the operating profit grew by 53 percent to SEK 65.5 million (42.8), which correspond to an operating margin of 27.3 percent (19.7). All in all, this means that 2015 was CellaVision's best year yet, and in line with our previously announced expectations of an operating income of SEK 65 million.  

 The development should also be seen in the light of 2014 being a good year for us. Seen over the past two years CellaVision's sales increased from SEK 179.9 million to SEK 239.4 million and the operating profit has moved from SEK 25.9 million to SEK 65.5 million, implying an improved operating margin in excess of 150% over two years.

 Sales in the final quarter of the year were SEK 61.6 million (72.5). The main explanation for lower sales is the veterinary order we received in the fourth quarter of 2014 that affects the comparison between the two quarters.

Final delivery of the other large veterinary order for more than SEK 30 million, most of which was delivered in the third quarter, was made according to plan in the fourth quarter. Our focus is now to optimize the installation so that the veterinary laboratories can use all the advantages that CellaVision's solutions offer.

 In the fourth quarter we also initiated contacts with new potential customers in the veterinary market and continue to evaluate this market both in the Americas and EMEA. However, the veterinary market is at an early stage of development and thus it is not clear how fast CellaVision can penetrate it.

 In the Americas our sales to human laboratories grew somewhat after a period of falling figures. One milestone is that we have now also installed our equipment at all 17 of the foremost hospitals in the USA. In APAC we saw continued positive development in both our key markets, Japan and China, and the region as a whole grew by about 18 percent in the quarter. In EMEA progress was somewhat weaker after a strong first half year and in the fourth quarter sales fell by about 11 percent.

 CellaVision is now implementing a series of activities aimed at strengthening the company long-term, with an expanded focus of evaluating establishment in new markets and regions. On the marketing side these activities include a newly started market support office in Dubai that will be operational in the first half of 2016 and a gradual expansion to new markets in APAC, with Korea as the next market.

 As regards our products and solutions, we started the launching process for CDMS 6.0 in the fourth quarter. CDMS 6.0 and an updated CellaVision® Remote Review are our latest software generation offering entirely new possibilities to link different laboratories into networks and perform analyses remotely. This considerably strengthens our offer to the larger laboratory chains. In the area of innovation we continue to focus on developing a technology platform for the 100,000 or more small and mid-sized human laboratories and approximately 5,000 veterinary laboratories.

 2015 was a year that we are very proud of. Having said that, we are now turning our sights on the future to continue developing CellaVision into an even more successful company.

Zlatko Rihter, President and Chief Executive Officer

Key Ratios

(MSEK) Oct-Dec 2015 Oct-Dec 2014 Full year 2015 Full year 2014
Net sales 61.6 72.5 239.4 216.9
Gross profit 46.4 50.5 174.2 145.1
Operating profit 16.4 16.8 65.5 42.8
Operating margin, % 26.7 23.2 27.3 19.7
Profit/loss before tax 16.8 16.6 65.6 43.4
Return on operating capital % - - 92.0 62.0
Equity ratio, % 83.0 75.0 83.0 75.0
Cash flow for the period 8.1 -6.6 54.8 -6.0

Questions concerning the report can be addressed to:

Zlatko Rihter, VD, CellaVision AB

Tel: 0733-62 11 06. E-post: zlatko.rihter@cellavision.se

Magnus Blixt, CFO, CellaVision AB

Tel: 0708-33 81 68. E-post: magnus.blixt@cellavision.se

Link text: CellaVision AB Year-end bulletin 2015

CellaVision AB Year-end bulletin 2015

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: CellaVision AB via Globenewswire




Kurs- und weitere Informationen zum Thema:


Aktuelle Diskussionen zum Thema:

Aktuelle Nachrichten zum Unternehmen:

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Weitere Meldungen
08:25 CellaVision AB : Year-end b.
08:05 Kesko's comparable sales de.
08:05 DNO ASA: Notification - Ho.
07:05 Aker Solutions ASA: Fourth.
07:05 REC Silicon ASA - Fourth .
07:00 EQS-Adhoc: Zug Estates 20.
11.02 Ad hoc: SinnerSchrader AG.
11.02 Ad hoc: SINGULUS TECHNO.
11.02 CORRECTION: L'Oréal: News.
11.02 Ad hoc: Cashcloud AG: Ver.
11.02 L'Oréal: News Release: "201.
11.02 ASSYSTEM : 2015 Consolid.
11.02 Ad hoc: Biotest AG: Korrek.
11.02 Ossur Hf : insider trading
11.02 Ad hoc: GESCO AG erhöht.
11.02 Annual Report for FLSmidth.
11.02 Ossur Hf : Insider trading
11.02 Ossur Hf : Share buy-back .
11.02 Ad hoc: Basler AG: Vorläuf.
11.02 Rezidor extends agreement .
11.02 Aspo Group's Financial Stat.
11.02 Ad hoc: Biotest AG: Biotes.
11.02 Hexagon Composites ASA: .
11.02 Kitron: Strategy and targets.
11.02 Kitron: Q4 2015 - Improved.
11.02 Kinnevik resolves to repurch.
11.02 Kinnevik: Year-end release 2.
11.02 DNO ASA Reports 2015 R.

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 11136 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Paion: Absturz ins Bodenlose!
Experte: Stefan Hofmann, STOCK-WORLD
Nordex: findet die Aktie ...
Robert Sasse, (08:38)
Experte: Robert Sasse,
Börsengeflüster: #TECAN – ...
DAX® (Weekly) - ...
Jörg Scherer, HSBC Trinkaus (08:34)
Experte: Jörg Scherer, HSBC Trinkaus
adidas AG: weltweit ...
Volker Gelfarth, (08:30)
Experte: Volker Gelfarth,
Caledonia Mining sichert ...
Jörg Schulte, JS-Research (08:22)
Experte: Jörg Schulte, JS-Research
Put auf DAX: Wie tief ...
Jürgen Sterzbach, boerse-daily.de (08:15)
Experte: Jürgen Sterzbach, boerse-daily.de
Gutes Timing: Turbo Bull ...
Carsten Englert, (08:10)
Experte: Carsten Englert,
Deutsche Bank hat ein “52 ...
Feingold-Research, (08:00)
Experte: Feingold-Research,
Deutsche Bank: Aktie ...
Christian Zoller, www.boerse-daily.de (07:49)
Experte: Christian Zoller, www.boerse-daily.de
Daimler: Spinnt der Markt?
Holger Steffen, (07:38)
Experte: Holger Steffen,
EuroStoxx50-Deep Express-...
Walter Kozubek, (07:24)
Experte: Walter Kozubek,
Devin Sage TXA Trading ...
Devin Sage, Technische-X-Analyse.de (11.02.16)
Experte: Devin Sage, Technische-X-Analyse.de
Niquet's World
Neues vom Portal
Wie man als Kleinanleger in Gold anlegt
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen